Evidence map›Paper›PMID 38082441›Full record

ArticleBMC cancer2023

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.

Jia Zhao, Simeng Zhang, Xiaoyu Guo, Ce Li, Bowen Yang, Xiujuan Qu, Shuo Wang

Open access · goldAbstract readNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jia Zhao *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Simeng Zhang *Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiaoyu GuoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ce LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Bowen YangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. xjqu@cmu.edu.cn.
Shuo WangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. suresure_wang@hotmail.com.
China Medical University · CNFirst Hospital of China Medical University · CNMinistry of Education · KN

Funding

National Natural Science Foundation of China 82203846Science and Technology Plan Project of Liaoning Province 2021-BS-102Scientist partner between China Medical University and Shenyang Branch of Chinese Academy of Sciences project ZHB2022002
6 · The paper itself

Abstract

backgroundThe combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous cell carcinoma (ESCC). However, there is no consensus on which chemotherapy regimen combined with PD-1 has better efficacy. To deal with this important issue in the first-line treatment of patients with ESCC, a network meta-analysis (NMA) was performed.

methodsData were collected from eligible studies searched in Medline, Web of Science, PubMed, the Cochrane Library and Embase. The pooled hazard ratio (HR) for the OS, and PFS, odds ratio (OR) for the objective response rate (ORR) and ≥ 3 grade treatment-related adverse events (≥ 3TRAEs) were estimated to evaluate the efficacy of PD-1 inhibitors combined with TP or FP.

resultsFive RCTs and one retrospective study involving 3685 patients and evaluating four treatments were included in this NMA. Compared to other treatments, PD-1 + TP was better. For the PFS, the HRs for PD-1 + TP compared to PD-1 + FP, TP and FP were 0.59 (0.44, 0.80), 0.56 (0.51, 0.61) and 0.45 (0.37, 0.56) respectively. For the OS, PD-1 + TP was also a better treatment compared to other treatments. The HRs were 0.74 (0.56, 0.96), 0.64 (0.57, 0.71), 0.53 (0.43, 0.67) respectively. For the ORR, there was no significant difference between PD-1 + TP and PD-1 + FP, and the ORs were 1.2 (0.69, 2.11). Compare with TP and FP, PD-1 + TP had an obvious advantage, ORs were 2.5 (2.04, 3.04) and 2.95 (1.91, 4.63). For ≥ 3TRAEs, PD-1 + TP compared to other treatments, ORs were 1.34 (0.74, 2.46) and 1.13 (0.92, 1.38) and 2.23 (1.35, 3.69).

conclusionPD-1 + TP significantly improved both PFS and OS compared to PD-1 + FP. Taking into account both efficacy and safety, PD-1 + TP may be a superior first-line treatment option for ESCC.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsCisplatinHumansImmune Checkpoint InhibitorsPaclitaxelProgrammed Cell Death 1 ReceptorRetrospective StudiesCisplatinImmune Checkpoint InhibitorsPaclitaxelProgrammed Cell Death 1 ReceptorCisplatinEsophageal squamous carcinomaMeta analysisPaclitaxelPD-1 inhibitor

Identifiers

PMID38082441
PMCPMC10714592
OpenAlexW4389543270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.